Pedersen, Louise Rasmussen and Maggie Fick COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as the ...

A woman has taken to the internet to share the biggest difference she experienced when switching between GLP-1 drugs Wegovy ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong international demand for weight-loss drugs ...

Reuters further highlighted that Novo Nordisk A/S (NYSE:NVO), which initially celebrated the success of its obesity drug, has ...

Novo Nordisk launched a bid valued at up to $9 billion for obesity-drug developer Metsera, hoping to trump an already agreed-on deal Pfizer made for the U.S. company last month.

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited ...

Denmark's Novo Nordisk launched a rival bid for U. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

Novo Nordisk raises its bid for obesity drugmaker Metsera to outmanoeuvre Pfizer, reshaping the fast-growing weight-loss ...

Danone is expanding into GLP-1 nutrition with dairy, microbiome solutions, and plant-based shakes. Three key moves shaping ...